Neonc Technologies Holdings, Inc.

Neonc Technologies Holdings, Inc.

NTHI·NASDAQ

$4.35

-4.2%
HealthcareBiotechnology

Neonc Technologies Holdings, Inc. develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.

At a Glance

Live Snapshot
Market Cap$86.98M
EPS-3.2300
P/E Ratio-1.35
Earnings Date06/03/2026

nthi

Total Payables

Last Annual Value

12.01M

3-Year CAGR

108%

5-Year CAGR

86%

10-Year CAGR

36%

Neonc Technologies Holdings, Inc.

Neonc Technologies Holdings, Inc. Competitors Analysis of Total Payables

NTHI · NASDAQ
CompanyTotal Payables
CAGR 3Y
CAGR 5Y
CAGR 10Y
12.01M
16.7%86.1%N/A 
921.00K
-16.6%-4.1%-1.4%
IVVD logo
Invivyd, Inc.
NASDAQ:IVVD
13.74M
20.0%18.9%N/A
OABI logo
OmniAb, Inc.
NASDAQ:OABI
1.88M
-24.8%-13.7%N/A
2.95M
-19.4%6.6%5.1%
1.17M
36.4%-15.1%-6.8%
2.21M
-11.3%4.4%-4.3%
0.00
N/AN/AN/A
14.44M
-1.8%8.1%18.8%
3.47M
12.5%29.5%N/A
6.09M
28.1%24.6%N/A
Neonc Technologies Holdings, Inc.

Neonc Technologies Holdings, Inc. Fair Value Envelope

NTHI · NASDAQ

Our analysis suggests that NTHI has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.35, this represents a potential HIDDEN relative to our calculated worth for Neonc Technologies Holdings, Inc..

Intrinsic Value
Current Price: $4.35